Gout is the most common inflammatory arthritis affecting 1-2% of the population. It is a very common problem presenting to ...

HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Innorna, a clinical--stage biotech company advancing RNA medicines, today announced that the U.S. Food and ...

Understanding the type of arthritis, its causes, and management options is the first step toward living well with the condition.

Patients who are prescribed higher daily doses of the medication buprenorphine for opioid use disorder are significantly more ...

Treatment with GLP-1 RAs for T2D and obesity is associated with increased risk for osteoporosis, gout, and osteomalacia compared with nonuse.

GLP-1 receptor agonist use was linked to a significantly higher risk for osteoporosis, gout, and osteomalacia over 5 years.

GLP-1 receptor agonists appear to be associated with an increased risk for osteoporosis and other orthopedic conditions.

People who take GLP-1 medications for several years may face a higher risk of developing osteoporosis, gout, and osteomalacia, according to new research presented Monday at the an ...

STOCKHOLM, Feb. 9, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) Sobi® (STO: SOBI) and Arthrosi Therapeutics, Inc. (Arthrosi) announced today the completion of the acquisition of Arthrosi by ...

Racial disparities in gout and gout treatment are an ongoing but tractable problem, research at the 2025 American College of Rheumatology (ACR)'s annual meeting suggested. In a 10-year ...

Gout, the most common form of inflammatory arthritis, often coexists with comorbidities that require integrated assessment and treatment. The burden of cardiovascular-kidney-metabolic (CKM) ...